Market Research Report
2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report
|Published by||Datamonitor Healthcare||Product code||914886|
|Published||Content info||117 Pages
Delivery time: 1-2 business days
|2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report|
|Published: October 18, 2019||Content info: 117 Pages||
The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1 2019. Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer. Key pipeline updates for more established drugs were highly featured including Keytruda for non-small lung cancer and Kisqali for breast cancer.
This post-meeting report features summaries of a few key topics along with commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.